Alzamend Neuro Management

Management criteria checks 4/4

Alzamend Neuro's CEO is Stephan Jackman, appointed in Nov 2018, has a tenure of 5.75 years. total yearly compensation is $443.62K, comprised of 78.9% salary and 21.1% bonuses, including company stock and options. directly owns 0.036% of the company’s shares, worth $646.94. The average tenure of the management team and the board of directors is 5.3 years and 3.2 years respectively.

Key information

Stephan Jackman

Chief executive officer

US$443.6k

Total compensation

CEO salary percentage	78.9%
CEO tenure	5.8yrs
CEO ownership	0.04%
Management average tenure	5.3yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

CEO Compensation Analysis

How has Stephan Jackman's remuneration changed compared to Alzamend Neuro's earnings?
Date	Total Compensation	Salary	Company Earnings
Apr 30 2024	US$444k	US$350k	-US$10m
Jan 31 2024	n/a	n/a	-US$12m
Oct 31 2023	n/a	n/a	-US$15m
Jul 31 2023	n/a	n/a	-US$15m
Apr 30 2023	US$2m	US$300k	-US$15m
Jan 31 2023	n/a	n/a	-US$15m
Oct 31 2022	n/a	n/a	-US$13m
Jul 31 2022	n/a	n/a	-US$13m
Apr 30 2022	US$473k	US$303k	-US$12m
Jan 31 2022	n/a	n/a	-US$10m
Oct 31 2021	n/a	n/a	-US$8m
Jul 31 2021	n/a	n/a	-US$6m
Apr 30 2021	US$225k	US$225k	-US$5m
Jan 31 2021	n/a	n/a	-US$5m
Oct 31 2020	n/a	n/a	-US$5m
Jul 31 2020	n/a	n/a	-US$5m
Apr 30 2020	US$2m	US$188k	-US$4m
Jan 31 2020	n/a	n/a	-US$4m
Oct 31 2019	n/a	n/a	-US$4m
Jul 31 2019	n/a	n/a	-US$4m
Apr 30 2019	US$3m	US$50k	-US$5m

Compensation vs Market: Stephan's total compensation ($USD443.62K) is below average for companies of similar size in the US market ($USD691.65K).

Compensation vs Earnings: Stephan's compensation has been consistent with company performance over the past year.

CEO

Stephan Jackman (48 yo)

5.8yrs

Tenure

US$443,617

Compensation

Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and has been its Director since September 2020. Mr. Jackman has experience in administration, business a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephan Jackman	CEO & Director	5.8yrs	US$443.62k	0.036% $ 646.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	1.98% $ 35.6k
David Katzoff	Chief Financial Officer	2yrs	US$150.00k	0.064% $ 1.2k
Henry C. Nisser	Executive VP	5.3yrs	US$50.00k	0% $ 0
Kenneth Cragun	Senior Vice President of Finance	3.2yrs	no data	0% $ 0

5.3yrs

Average Tenure

55yo

Average Age

Experienced Management: ALZN's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephan Jackman	CEO & Director	3.9yrs	US$443.62k	0.036% $ 646.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	1.98% $ 35.6k
Henry C. Nisser	Executive VP	3.9yrs	US$50.00k	0% $ 0
William Horne	Chairman of the Board	8.2yrs	US$50.00k	0.79% $ 14.2k
Mark Gustafson	Independent Director	3.2yrs	US$25.00k	0.048% $ 854.0
Lynne McGrath	Independent Director	3.2yrs	US$25.00k	0.059% $ 1.1k
Thomas Wisniewski	Member of Scientific Advisory Board	5.1yrs	no data	no data
Eric McDade	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Oram	Independent Director	3.2yrs	US$25.00k	0.079% $ 1.4k
Andrew Woo	Independent Director	3.2yrs	US$25.00k	0.079% $ 1.4k
Terri Hunter	Member of Scientific Advisory Board	2.3yrs	no data	no data

3.2yrs

Average Tenure

56.5yo

Average Age

Experienced Board: ALZN's board of directors are considered experienced (3.2 years average tenure).

Alzamend Neuro Management

Management criteria checks 4/4

Key information

Recent management updates

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

High number of new and inexperienced directors

Alzamend Neuro, Inc. Announces CFO Changes

No independent directors

Recent updates

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro closes $14.4M IPO

Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age